NASDAQ:IRON Disc Medicine (IRON) Stock Price, News & Analysis $59.65 -0.01 (-0.02%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$59.75 +0.10 (+0.17%) As of 08/29/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Disc Medicine Stock (NASDAQ:IRON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Disc Medicine alerts:Sign Up Key Stats Today's Range$59.14▼$60.6850-Day Range$51.13▼$61.1052-Week Range$30.82▼$68.73Volume214,790 shsAverage Volume315,800 shsMarket Capitalization$2.07 billionP/E RatioN/ADividend YieldN/APrice Target$98.30Consensus RatingBuy Company Overview Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts. Read More Disc Medicine Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreIRON MarketRank™: Disc Medicine scored higher than 72% of companies evaluated by MarketBeat, and ranked 276th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDisc Medicine has received a consensus rating of Buy. The company's average rating score is 3.09, and is based on 10 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageDisc Medicine has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Disc Medicine's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Disc Medicine are expected to decrease in the coming year, from ($4.07) to ($5.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Disc Medicine is -13.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Disc Medicine is -13.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDisc Medicine has a P/B Ratio of 3.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Disc Medicine's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.66% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Disc Medicine has recently decreased by 20.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDisc Medicine does not currently pay a dividend.Dividend GrowthDisc Medicine does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.66% of the float of Disc Medicine has been sold short.Short Interest Ratio / Days to CoverDisc Medicine has a short interest ratio ("days to cover") of 6.1.Change versus previous monthShort interest in Disc Medicine has recently decreased by 20.14%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.32 News SentimentDisc Medicine has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Disc Medicine this week, compared to 6 articles on an average week.Search Interest10 people have searched for IRON on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Disc Medicine insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,006,371.00 in company stock.Percentage Held by InsidersOnly 3.64% of the stock of Disc Medicine is held by insiders.Percentage Held by Institutions83.70% of the stock of Disc Medicine is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Disc Medicine's insider trading history. Receive IRON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Disc Medicine and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IRON Stock News HeadlinesKevin Bitterman Sells 2,287 Shares of Disc Medicine (NASDAQ:IRON) StockAugust 27 at 6:55 AM | insidertrades.comInsider Selling: Disc Medicine, Inc. (NASDAQ:IRON) Director Sells 7,212 Shares of StockAugust 16, 2025 | insidertrades.comTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predicted it all. Even crazier, this secret accurately called every major financial event in recent history … Now it's signaling something very scary is about to hit the market again … | Weiss Ratings (Ad)Disc Medicine, Inc. (NASDAQ:IRON) Director Sells $518,351.68 in StockAugust 2, 2025 | insidertrades.comStocks To Watch: Disc Medicine Sees Relative Strength Rating Jump To 81August 27 at 10:52 AM | msn.comAnalysts Set Disc Medicine, Inc. (NASDAQ:IRON) PT at $95.73August 20, 2025 | americanbankingnews.comDisc Medicine (NASDAQ:IRON) Stock Price Expected to Rise, Morgan Stanley Analyst SaysAugust 20, 2025 | americanbankingnews.comDisc Medicine (IRON) Receives a Buy from TD CowenAugust 9, 2025 | theglobeandmail.comSee More Headlines IRON Stock Analysis - Frequently Asked Questions How have IRON shares performed this year? Disc Medicine's stock was trading at $63.40 at the beginning of the year. Since then, IRON stock has decreased by 5.9% and is now trading at $59.65. How were Disc Medicine's earnings last quarter? Disc Medicine, Inc. (NASDAQ:IRON) announced its earnings results on Thursday, August, 7th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by $0.41. Who are Disc Medicine's major shareholders? Disc Medicine's top institutional shareholders include Frazier Life Sciences Management L.P. (4.78%), JPMorgan Chase & Co. (2.44%), Geode Capital Management LLC (1.73%) and Bain Capital Life Sciences Investors LLC (1.68%). Insiders that own company stock include Venture Fund X LP Atlas, Holdings A/S Novo, Orbimed Advisors Llc, Kevin Bitterman, Mona Ashiya, John D Quisel, Pamela Stephenson, Jean M Franchi, William Jacob Savage, Jonathan Yen-Wen Yu, Rahul Khara, Brian Richard Macdonald, Joanne Bryce and William Richard White. View institutional ownership trends. How do I buy shares of Disc Medicine? Shares of IRON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Disc Medicine own? Based on aggregate information from My MarketBeat watchlists, some other companies that Disc Medicine investors own include NVIDIA (NVDA), Broadcom (AVGO), e.l.f. Beauty (ELF), Arista Networks (ANET), Builders FirstSource (BLDR), Novo Nordisk A/S (NVO) and Jabil (JBL). Company Calendar Last Earnings8/07/2025Today8/30/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IRON CIK1816736 Webwww.discmedicine.com Phone617-401-4400FaxN/AEmployees30Year FoundedN/APrice Target and Rating Average Price Target for Disc Medicine$98.30 High Price Target$132.00 Low Price Target$75.00 Potential Upside/Downside+64.8%Consensus RatingBuy Rating Score (0-4)3.09 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($4.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$109.36 million Net MarginsN/A Pretax MarginN/A Return on Equity-26.60% Return on Assets-24.58% Debt Debt-to-Equity Ratio0.05 Current Ratio32.11 Quick Ratio32.11 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$17.67 per share Price / Book3.38Miscellaneous Outstanding Shares34,770,000Free Float33,501,000Market Cap$2.07 billion OptionableNot Optionable Beta0.77 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:IRON) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredTrump’s national nightmare is hereAI is no longer just about chatbots — it’s becoming the backbone of the global economy. While U.S. firms push ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Disc Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Disc Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.